Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?

We report a case of Guillain-Barré syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the COVID-19 vaccination campaign progresses worldwide, GBSs vaccine-related have been increasingly reported. After reviewing the available literat...

Descripción completa

Detalles Bibliográficos
Autores principales: Introna, Alessandro, Caputo, Francesca, Santoro, Carlo, Guerra, Tommaso, Ucci, Maria, Mezzapesa, Domenico Maria, Trojano, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360997/
https://www.ncbi.nlm.nih.gov/pubmed/34418708
http://dx.doi.org/10.1016/j.clineuro.2021.106887
_version_ 1783737864536719360
author Introna, Alessandro
Caputo, Francesca
Santoro, Carlo
Guerra, Tommaso
Ucci, Maria
Mezzapesa, Domenico Maria
Trojano, Maria
author_facet Introna, Alessandro
Caputo, Francesca
Santoro, Carlo
Guerra, Tommaso
Ucci, Maria
Mezzapesa, Domenico Maria
Trojano, Maria
author_sort Introna, Alessandro
collection PubMed
description We report a case of Guillain-Barré syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the COVID-19 vaccination campaign progresses worldwide, GBSs vaccine-related have been increasingly reported. After reviewing the available literature, considering the annual incidence of GBS, in this historical moment, the public health systems cannot afford an unjustified distrust in vaccines, caused by misinterpretation of epidemiological data. Nonetheless, it is important for clinicians to promptly recognize neurological complications potentially associated with COVID-19 vaccinations and report them to pharmacovigilance agencies.
format Online
Article
Text
id pubmed-8360997
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-83609972021-08-13 Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? Introna, Alessandro Caputo, Francesca Santoro, Carlo Guerra, Tommaso Ucci, Maria Mezzapesa, Domenico Maria Trojano, Maria Clin Neurol Neurosurg Case Report We report a case of Guillain-Barré syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the COVID-19 vaccination campaign progresses worldwide, GBSs vaccine-related have been increasingly reported. After reviewing the available literature, considering the annual incidence of GBS, in this historical moment, the public health systems cannot afford an unjustified distrust in vaccines, caused by misinterpretation of epidemiological data. Nonetheless, it is important for clinicians to promptly recognize neurological complications potentially associated with COVID-19 vaccinations and report them to pharmacovigilance agencies. Elsevier B.V. 2021-09 2021-08-13 /pmc/articles/PMC8360997/ /pubmed/34418708 http://dx.doi.org/10.1016/j.clineuro.2021.106887 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Introna, Alessandro
Caputo, Francesca
Santoro, Carlo
Guerra, Tommaso
Ucci, Maria
Mezzapesa, Domenico Maria
Trojano, Maria
Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
title Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
title_full Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
title_fullStr Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
title_full_unstemmed Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
title_short Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
title_sort guillain-barré syndrome after astrazeneca covid-19-vaccination: a causal or casual association?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360997/
https://www.ncbi.nlm.nih.gov/pubmed/34418708
http://dx.doi.org/10.1016/j.clineuro.2021.106887
work_keys_str_mv AT intronaalessandro guillainbarresyndromeafterastrazenecacovid19vaccinationacausalorcasualassociation
AT caputofrancesca guillainbarresyndromeafterastrazenecacovid19vaccinationacausalorcasualassociation
AT santorocarlo guillainbarresyndromeafterastrazenecacovid19vaccinationacausalorcasualassociation
AT guerratommaso guillainbarresyndromeafterastrazenecacovid19vaccinationacausalorcasualassociation
AT uccimaria guillainbarresyndromeafterastrazenecacovid19vaccinationacausalorcasualassociation
AT mezzapesadomenicomaria guillainbarresyndromeafterastrazenecacovid19vaccinationacausalorcasualassociation
AT trojanomaria guillainbarresyndromeafterastrazenecacovid19vaccinationacausalorcasualassociation

Ejemplares similares